Opportunity Information: Apply for RFA IP 11 013
Apply for RFA IP 11 013
- The Centers for Disease Control and Prevention in the health sector is offering a public funding opportunity titled "Influenza Vaccine Efficacy in Tropical and Developing Countries" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.283 Centers for Disease Control and PreventionInvestigations and Technical Assistance.
- This funding opportunity was created on Dec 30, 2010 and posted on Dec 30, 2010.
- Applicants must submit their applications by Mar 14, 2011 On time submission requires that electronic applications be error free and made available to CDC for processing from eRA Commons on or before the deadline date. Applications must be submitted to and validated successfully by Grants.gov/eRA Commons no later than 500 PM Eastern Time. Note.HHS/CDC grant submission procedures do not provide a period of time beyond the application due date to correct any error or warning notices of noncompliance with application instructions that are identified by Grants.gov or eRA systems (i.e., error correction window).. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $1,250,000.00 in funding.
- The number of recipients for this funding is limited to 2 candidate(s).
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
- Eligibility is limited to PATH and the University of Alabama, Birmingham who have been funded under RFA IP08 002 since 2008 because
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The grant opportunity titled "Influenza Vaccine Efficacy in Tropical and Developing Countries" focuses on closing a major evidence gap about how influenza vaccination works in real-world settings outside of temperate, high-income countries. The CDC notes that while some studies suggest vaccinating certain groups can protect not only the people who receive the vaccine but also others around them by reducing transmission (often described as indirect or community-level protection), there have been very few rigorous studies measuring these indirect effects at the household or broader community level. Beyond a historical observational study conducted during the 1968 influenza pandemic, the available data are limited on whether vaccinating part of a community measurably reduces illness among people who are not vaccinated. This matters especially for groups that may not respond strongly to vaccination, such as very young children, older adults, or people with underlying health conditions, because they might benefit substantially if transmission in their environment decreases.
A central motivation of the program is that almost no information was available at the time on influenza vaccine effectiveness in tropical, developing-country populations, where routine influenza vaccination had been limited. The CDC highlights that influenza transmission dynamics may differ substantially in these settings due to factors like higher population density, different patterns of social mixing, larger or more multigenerational households, variations in school attendance and classroom crowding, and distinct day-to-day interaction patterns compared with the United States and other developed countries in temperate climates. Because these factors can change who infects whom, how quickly outbreaks spread, and which age groups drive transmission, the CDC is seeking studies that can generate evidence directly applicable to tropical and developing contexts rather than relying on assumptions based on temperate-country data.
The opportunity is also framed as a preparedness investment. The CDC emphasizes that the next influenza pandemic could emerge from a tropical, developing country, making it critical to understand how vaccination could reduce spread and disease burden in those regions. The findings are expected to support more realistic pandemic planning, including strategies for allocating vaccine when supply is limited, which is a common constraint early in a pandemic. In addition to informing pandemic response options, the research is expected to improve general scientific understanding of how influenza transmission interacts with social structure and existing population immunity. The CDC also anticipates that results will contribute valuable baseline information on influenza epidemiology and disease burden in tropical regions and help clarify the potential public health value of expanding seasonal influenza vaccination programs in developing countries.
From an administrative standpoint, this was a CDC discretionary funding opportunity offered through a cooperative agreement, which typically means the agency expects substantial involvement in the planning or execution of the work compared with a standard grant. The Funding Opportunity Number is RFA IP 11 013, and it falls under CFDA 93.283 (CDC Investigations and Technical Assistance). The CDC anticipated making two awards, with an award ceiling of $1,250,000 and no cost sharing or matching requirement. The opportunity was posted on December 30, 2010, and the application deadline was March 14, 2011, with a strict requirement that electronic submissions be validated by Grants.gov and eRA Commons by 5:00 PM Eastern Time, and with no extra error-correction window after the deadline. Eligibility was restricted to PATH and the University of Alabama at Birmingham because both had already been funded under an earlier related announcement (RFA IP08 002) since 2008, indicating this funding was designed as a continuation or expansion of existing work rather than an open competition. The administering agency was the Centers for Disease Control and Prevention, and technical assistance for accessing the announcement was routed through CDC’s Procurement and Grants Office Technical Information and Management Section.
FAQs: Influenza Vaccine Efficacy in Tropical and Developing Countries (RFA IP 11 013)
What is the title of this grant opportunity?
The opportunity is titled "Influenza Vaccine Efficacy in Tropical and Developing Countries."
Which federal agency is offering this opportunity?
The administering agency is the Centers for Disease Control and Prevention (CDC).
What is the Funding Opportunity Number (FOA number)?
The Funding Opportunity Number is RFA IP 11 013.
What CFDA program is this opportunity under?
This opportunity falls under CFDA 93.283 (CDC Investigations and Technical Assistance).
What type of funding mechanism is being used?
The CDC offered this as a cooperative agreement, which generally indicates substantial CDC involvement in the planning and/or execution of the funded work compared with a standard grant.
What is the main purpose of the program?
The program aims to close a major evidence gap on how influenza vaccination performs in real-world settings outside temperate, high-income countries, with a focus on tropical and developing-country contexts.
What evidence gap is the CDC trying to address?
The CDC highlighted limited rigorous evidence on whether vaccinating part of a community reduces influenza illness among people who are not vaccinated. In particular, there have been very few rigorous studies measuring indirect (community-level) protection at the household or broader community level.
What is meant by indirect or community-level protection in this announcement?
Indirect or community-level protection refers to the idea that vaccinating some people can reduce transmission, potentially protecting others around them (including unvaccinated individuals) by lowering the amount of influenza spread in the community.
Why is measuring indirect effects considered important?
It matters especially for people who may not respond strongly to vaccination, such as very young children, older adults, or individuals with underlying health conditions, because they may benefit if influenza transmission decreases in their environment.
What does the announcement say about existing data on indirect effects?
Beyond a historical observational study conducted during the 1968 influenza pandemic, the CDC noted that available data were limited on whether partial community vaccination measurably reduces illness among unvaccinated people.
Why is the focus on tropical and developing countries specifically?
The CDC emphasized that, at the time, there was almost no information on influenza vaccine effectiveness in tropical, developing-country populations, where routine influenza vaccination had been limited.
Why might influenza transmission differ in tropical and developing settings?
The announcement notes that transmission dynamics may differ due to factors such as higher population density, different social mixing patterns, larger or more multigenerational households, variations in school attendance and classroom crowding, and distinct day-to-day interaction patterns compared with the United States and other developed countries in temperate climates.
How do these contextual factors affect the research need?
Because these factors can change who infects whom, how quickly outbreaks spread, and which age groups drive transmission, the CDC sought evidence directly applicable to tropical and developing contexts rather than relying on assumptions based on temperate-country data.
How is this opportunity connected to pandemic preparedness?
The CDC framed the program as a preparedness investment, emphasizing that the next influenza pandemic could emerge from a tropical, developing country and that understanding vaccination impact in those regions could help reduce spread and disease burden.
How could results be used in pandemic planning?
The findings were expected to support more realistic pandemic planning, including strategies for allocating vaccine when supply is limited, a constraint that is common early in a pandemic.
Does the announcement mention benefits beyond pandemic response?
Yes. The research was expected to improve scientific understanding of how influenza transmission interacts with social structure and existing population immunity, contribute baseline information on influenza epidemiology and disease burden in tropical regions, and help clarify the public health value of expanding seasonal influenza vaccination programs in developing countries.
How many awards did the CDC anticipate making?
The CDC anticipated making two awards.
What was the maximum award amount (award ceiling)?
The award ceiling was $1,250,000.
Was cost sharing or matching required?
No. The announcement stated there was no cost sharing or matching requirement.
When was the opportunity posted?
The opportunity was posted on December 30, 2010.
What was the application deadline?
The application deadline was March 14, 2011.
What were the submission and validation requirements?
Electronic submissions had to be validated by Grants.gov and eRA Commons by 5:00 PM Eastern Time, and the announcement specified there was no extra error-correction window after the deadline.
Was this an open competition for all eligible applicants?
No. Eligibility was restricted to PATH and the University of Alabama at Birmingham.
Why was eligibility restricted to only PATH and the University of Alabama at Birmingham?
The announcement indicated both organizations had already been funded under an earlier related announcement (RFA IP08 002) since 2008, suggesting this funding was intended as a continuation or expansion of existing work rather than an open competition.
Where could applicants get technical assistance related to accessing the announcement?
Technical assistance for accessing the announcement was routed through CDC's Procurement and Grants Office Technical Information and Management Section.
Browse more opportunities from the same agency: Centers for Disease Control and Prevention
Browse more opportunities from the same category: Health
Next opportunity: Dimensions of Biodiversity
Previous opportunity: OJJDP FY 2011 Evaluations of Girls Delinquency Programs
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA IP 11 013
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA IP 11 013) also looked into and applied for these:
| Funding Opportunity |
|---|
| HIT Capacity Building Initiative for Ryan White HIV/AIDS Program AIDS Drug Assistance Program (ADAP) Grantee Sites Apply for HRSA 11 101 Funding Number: HRSA 11 101 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Sustainable Responses for Improving the Lives of Vulnerable Children and their Households Apply for RFA 617 11 000001 Funding Number: RFA 617 11 000001 Agency: Uganda USAID Kampala Category: Health Funding Amount: $29,500,000 |
| Research on Alcohol Related Public Policies such as Those Detailed in the Alcohol Policy Information System (R01) Apply for PA 11 087 Funding Number: PA 11 087 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Research on Alcohol Related Public Policies such as Those Detailed in the Alcohol Policy Information System (R03) Apply for PA 11 088 Funding Number: PA 11 088 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Research on Alcohol Related Public Policies such as Those Detailed in the Alcohol Policy Information System (R21) Apply for PA 11 089 Funding Number: PA 11 089 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| NHLBI Investigator Initiated Resource Related Research Projects (R24) Apply for PAR 11 090 Funding Number: PAR 11 090 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Rural Access to Emergency Devices Apply for HRSA 11 088 Funding Number: HRSA 11 088 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Emerging Infections Sentinel Network (EISN) Research Apply for RFA CK 11 002 Funding Number: RFA CK 11 002 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $407,000 |
| Effectiveness in an Intervention to Promote a Targeted Vaccination Program in the Obstetrician Gynecologist Setting Apply for RFA IP 11 009 Funding Number: RFA IP 11 009 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $300,000 |
| National Center for Chronic Disease Prevention and Health Promotion Conference Support Program Apply for CDC RFA DP11 1102 Funding Number: CDC RFA DP11 1102 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Genomic Resource Grants for Community Resource Projects (U41) Apply for PAR 11 095 Funding Number: PAR 11 095 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Enhanced Surveillance for New Vaccine Preventable Disease Apply for RFA IP 11 010 Funding Number: RFA IP 11 010 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,000,000 |
| Affordable Care Act Health Center Planning Grants Apply for HRSA 11 021 Funding Number: HRSA 11 021 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Annual Estimates of Influenza Vaccine Effectiveness for Preventing Laboratory Confirmed Influenza in the United States Apply for RFA IP 11 003 Funding Number: RFA IP 11 003 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $785,000 |
| Strategies to Improve Vaccination Coverage of Children in Child Care Centers (CCCs) and Preschools. Apply for RFA IP 11 006 Funding Number: RFA IP 11 006 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Economic Studies of Vaccines and Immunization Policies, Programs and Practices Apply for RFA IP 11 007 Funding Number: RFA IP 11 007 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| The Incidence and Etiology of Influenza Associated Community Acquired Pneumonia in Hospitalized Persons Study Apply for RFA IP 11 011 Funding Number: RFA IP 11 011 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Public Health Conference Support Program Apply for CDC RFA EH11 1105 Funding Number: CDC RFA EH11 1105 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $200,000 |
| Service Area Competition Additional Areas Apply for HRSA 11 163 Funding Number: HRSA 11 163 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Delta Health Initiative Apply for HRSA 11 090 Funding Number: HRSA 11 090 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA IP 11 013", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.